Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Starpharma Tumor Activity Equipment & Supplies In Europe
3 equipment items found
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® irinotecan is an improved version of irinotecan (Camptosar®), predominantly used for colorectal cancer. DEP® irinotecan is a novel, patented nanoparticle formulation of SN-38, the active metabolite of irinotecan, delivered using Starpharma’s proprietary DEP® technology. Irinotecan (Camptosar®) is a major cancer drug used to treat colorectal cancer with peak global ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...